文献速递肿瘤 PET/CT心脏核医学核素与放射性配体治疗

2-[18F]FDG PET/CT半定量指标评估IgG4相关疾病的心血管与非心血管表现及治疗反应

Semi-quantitative indices of 2-[18F]FDG PET/CT in assessing cardiovascular and non-cardiovascular manifestations of IgG4-related disease and treatment response.
PubMed 文献 · EJNMMI Res · 2023-03-17

回顾性研究纳入46例IgG4相关疾病(IgG4-RD)患者,分为心血管表现组8例和无心血管表现组38例,评估2-[18F]FDG PET/CT半定量参数SUVmax、MTV、TLG及TBR的作用。10例有治疗前后PET/CT的患者所有半定量参数显著下降,而总IgG和ESR无显著下降。结论认为PET/CT有助于确定多系统受累部位并排除无症状的心血管表现,半定量参数可用于评估治疗反应。

要点

  • 心血管病变组8例中37.5%为其他疾病影像评估时偶然发现,均无胸痛等心血管症状。
  • 10例治疗前后PET/CT患者SUVmax、MTV、TLG均显著下降,总IgG和ESR无显著下降。
  • SUVmax、MTV、TLG下降在有无心血管表现的患者中均得到重复。

核心结论

  • 2-[18F]FDG PET/CT是确定IgG4-RD多系统受累部位并排除无症状危及生命心血管表现的重要检查。
  • SUVmax、MTV、TLG和TBR等半定量参数可用于评估治疗反应。
  • 目前没有血清学替代指标能像2-[18F]FDG PET/CT那样量化疾病受累范围。

研究设计与样本

  • 回顾性研究,纳入46例确诊IgG4-RD且接受2-[18F]FDG PET/CT扫描的患者。
  • 按有无心血管表现分为8例心血管表现组和38例无心血管表现组。
  • 提取临床和实验室数据,与SUVmax、MTV、TLG三个半定量参数比较,心血管表现还评估组织-血本底比值(TBR)。
  • 在10例有免疫抑制治疗前后PET/CT的患者中比较治疗前后数据。

主要发现

  • 心血管病变组最常在因其他疾病影像评估时偶然发现(37.5%),无一例表现为胸痛或其他心血管症状。
  • 10例治疗前后PET/CT患者所有半定量参数均显著下降,总IgG或ESR无显著下降。
  • SUVmax、MTV、TLG治疗后下降在有无心血管表现的患者中均得到重复。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: IgG4-related disease (IgG4-RD) is a heterogeneous autoimmune disorder characterised by inflammatory lesions. Diagnostic imaging, such as 2-[18F]FDG PET/CT, is critical in evaluation of the disease, especially for potentially lethal cardiovascular manifestations. This retrospective study examines the usefulness of semi-quantitative parameters of 2-[18F]FDG PET/CT in monitoring IgG4-RD in patients with and without cardiovascular manifestations. METHODS: Patients diagnosed with IgG4-RD who underwent a 2-[18F]FDG PET/CT scan were identified and classified based on presence or absence of cardiovascular disease. Clinical and laboratory data were extracted and compared to three 2-[18F]FDG PET/CT semi-quantitative parameters: maximum standardised uptake value (SUVmax), metabolic tumour volume (MTV), and total lesion glycolysis (TLG). Tissue-to-background blood (TBR) values were also evaluated for cardiovascular manifestations. These data were also compared in patients before and after receiving immunosuppressive therapy. RESULTS: Forty-six patients identified were divided into an eight member subgroup of patients with cardiovascular manifestations, and a thirty-eight member subgroup of patients without. Patients with cardiovascular lesions were most frequently identified incidentally on imaging evaluation for other diseases (37.5%), with none presenting with chest pain or other cardiovascular symptoms. Ten patients with pre-treatment and post-treatment 2-[18F]FDG PET/CT scans demonstrated significant decreases in all semi-quantitative parameters, with no significant decrease in total IgG or ESR. The decrease in SUVmax, MTV, TLG following therapy was replicated in patients with and without cardiovascular manifestations. CONCLUSION: 2-[18F]FDG PET/CT is an important investigation to determine all sites of involvement in this multisystemic disease and to rule out life-threatening cardiovascular manifestations even in the absence of symptoms. Semi-quantitative parameters such as SUVmax, MTV, TLG, and TBR are useful in assessing treatment response in patients. There are no serological substitutes that can quantify the extent of disease involvement like 2-[18F]FDG PET/CT.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Chen M, Tang CYL, Fong WWS, et al. Semi-quantitative indices of 2-[18F]FDG PET/CT in assessing cardiovascular and non-cardiovascular manifestations of IgG4-related disease and treatment response. EJNMMI Res. 2023. PMID: 36930380. doi:10.1186/s13550-023-00972-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。